FDA Adverse Event Injury Summary report: N

CARPENTIER-EDWARDS® PERIMOUNT MAGNA¿ MITRAL PERICARDIAL BIOPROSTHESIS

MDR report key: 5470842 · Received March 1, 2016

Report

Report Number
2015691-2016-00614
Event Type
Injury
Date Received
March 1, 2016
Date of Event
February 5, 2016
Report Date
February 5, 2016
Manufacturer
EDWARDS LIFESCIENCES
Product Code
DYE
PMA / PMN Number
P860057/S029
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
MN, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

ATTEMPTS TO RETRIEVE ADDITIONAL INFORMATION AND RETURN OF THE DEVICE WERE UNSUCCESSFUL. HEALTHCARE PROVIDER REPORTED THAT THE DEVICE IS NOT AVAILABLE.

Additional Manufacturer Narrative · 1

ADDITIONAL MANUFACTURER NARRATIVE: THE DEVICE WAS NOT RETURNED TO EDWARDS FOR EVALUATION. ATTEMPTS TO RETRIEVE THE DEVICE ARE IN PROCESS. ATTEMPTS TO RETRIEVE ADDITIONAL INFORMATION WERE UNSUCCESSFUL. BASED ON THE INFORMATION RECEIVED THE CAUSE OF THE EVENT CANNOT BE DETERMINED. IF ADDITIONAL INFORMATION IS RECEIVED A SUPPLEMENTAL MDR WILL BE SUBMITTED. EDWARDS WILL CONTINUE TO REVIEW AND MONITOR ALL EVENTS. TRENDS ARE MONITORED ON A MONTHLY BASIS AND IF ACTION IS REQUIRED, APPROPRIATE INVESTIGATION WILL BE PERFORMED.

Description of Event or Problem · 1

ARTICLE: "THE CARPENTIER-EDWARDS PERIMOUNT MAGNA MITRAL VALVE BIOPROSTHESIS: INTERMEDIATE TERM - EFFICACY AND DURABILITY" PUBLISHED IN JOURNAL OF CARDIOTHORACIC SURGERY. DOI 10.1186/S13019-016-0412-4. ABSTRACT: BACKGROUND: THE CARPENTIER-EDWARDS PERIMOUNT MAGNA MITRAL VALVE BIOPROSTHESIS (EDWARDS LIFESCIENCES, (B)(4)) IS A LOW-PROFILE VERSION OF THE EARLIER PERIMOUNT VALVE THAT USES THE THERMAFIX PROCESS FOR ENHANCED CALCIUM REMOVAL. THE MAGNA VALVE HAS BEEN IN USE SINCE 2008, YET NO PUBLICATION, UNTIL NOW, HAS VERIFIED ITS INTERMEDIATE-TERM SAFETY AND EFFICACY. METHODS: FROM 2008 THROUGH 2011 (OUR 4-YEAR STUDY PERIOD), 70 MAGNA VALVES WERE IMPLANTED IN THE MITRAL POSITION AT A SINGLE INSTITUTION ((B)(4)). ECHOCARDIOGRAMS WERE PROSPECTIVELY INTERPRETED. FOR THIS STUDY, WE REVIEWED PATIENTS CHARTS; ENDPOINTS INCLUDED HEMODYNAMIC MEASUREMENTS, IN-HOSPITAL MORBIDITY AND MORTALITY, VALVE-RELATED EVENTS, RESOURCE UTILIZATION, AND 5-YEAR SURVIVAL RATES. RESULTS: THE MEAN PATIENT AGE WAS 68 YEARS; 43 % OF THE PATIENTS HAD NEW YORK HEART ASSOCIATION (NYHA) CLASS III OR IV DISEASE, AND 51.4 % HAD MODERATELY SEVERE, OR WORSE, MITRAL REGURGITATION (MR). FOR 43 % OF THE PATIENTS, THE MAGNA VALVE IMPLANTATION WAS A REOPERATION. FOR 83 %, THE MAGNA VALVE IMPLANTATION ALSO INCLUDED A CONCOMITANT CARDIAC PROCEDURE. THE MEDIAN SURVIVAL RATE WAS 4.7 YEARS AND 90 % OF PATIENTS WERE FREE FROM SIGNIFICANT STRUCTURAL VALVE DEGENERATION AT 5 YEARS. PREOPERATIVE ATRIAL FIBRILLATION, ISCHEMIC MR, INTRAAORTIC BALLOON PUMP PLACEMENT, CARDIOGENIC SHOCK, CARDIAC ARREST, AND RENAL FAILURE WERE ASSOCIATED WITH INCREASED MORTALITY. RIGHT VENTRICULAR SYSTOLIC PRESSURE DECREASED FROM 50 MMHG PREOPERATIVELY TO 40 MMHG POSTOPERATIVELY, ACCORDING TO OUR MATCHED-PAIR ANALYSIS (P = 0.003). PER THEIR FINAL ECHOCARDIOGRAM DURING OUR STUDY PERIOD, 98 % OF SURVIVING PATIENTS HAD TRIVIAL OR NO MR, ONE PATIENT HAD MILD MR, AND ONE PATIENT HAD SEVERE MR. CONCLUSIONS: OUR 5-YEAR EXPERIENCE INDICATES THAT THE MAGNA VALVE OFFERS EXCELLENT INTERMEDIATE-TERM DURABILITY AND SUBSTANTIAL ECHOCARDIOGRAPHIC IMPROVEMENT; ITS LOW-PROFILE DESIGN MAKE IT IDEAL FOR REOPERATIONS AND FOR CONCOMITANT CARDIAC PROCEDURES, INCLUDING VALVE REPLACEMENT. IN THIS CASE, IT WAS LEARNED THAT A VALVE EXPLANTED AFTER AN IMPLANT DURATION OF TWO (2) YEARS DUE TO LVOT OBSTRUCTION BY A STRUT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
128298 CARPENTIER-EDWARDS® PERIMOUNT MAGNA¿ MITRAL PERICARDIAL BIOPROSTHESIS REPLACEMENT HEART VALVE DYE EDWARDS LIFESCIENCES 7000TFX

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization| R